Page 69 - Human Use News Today

Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with an estimated prevalence of 1.36 per million individuals

GAITHERSBURG, Md., May 26, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M adjuvant, today announced that Nuvaxovid

Therapy has been developed for use among children and adolescents with growth hormone deficiency - News - PharmaTimes

Biotechnology company Novavax, Inc. (NVAX) announced Friday that Nuvaxovid (NVX-CoV2373) has been recommended for full Marketing Authorization (MA) for use as a primary series in individuals aged 12 and older and as a booster in individuals aged 18 and older for the prevention of COVID-19 in the European Union (EU).

May 26, 2023 Basel, May 26, 2023 - The European Medicines Agencys Committee for Medicinal Products for Human Use has recommended the revocation of the conditional... | May 26, 2023

Recommendation based on results from the Phase 3 CheckMate -816 trial, in which Opdivo with chemotherapy demonstrated improved event-free survival and pathologic complete response compared to... | May 26, 2023

As part of a new Asia-Pacific (APAC) Life Sciences and Health Care webinar program designed both for companies with commercial interests in APAC and for companies based in the region,...

You are locking them up in cages, you are the one sending them to be with human traffickers, letting the women be abused and the kids brutalized. and the biden administration thrives in darkness. they trust the corrupt corporate media, never to report on their disasters and what you do and a handful of others is just tell the truth. >> hannity: lets talk a little bit about the debt ceiling. >> yeah. >> hannity: there are now 44 senators, if you include senator kennedy, i dont think he signed but...

The prevalence of dry eye disease has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of dry eye disease and the growing

/PRNewswire/ -- DelveInsights Dry Eye Disease Pipeline Insight – 2023 report provides comprehensive global coverage of pipeline dry eye disease therapies in...